FRACTYL HEALTH, INC.

Fractyl Health develops metabolic therapeutics targeting type 2 diabetes and obesity through procedural and gene therapy approaches. The company's primary product candidate is the Revita DMR System, an outpatient procedural therapy designed to modify duodenal dysfunction—a pathological condition resulting from high-fat, high-sugar diets that contributes to metabolic disease initiation. The company also develops Rejuva, a gene therapy platform utilizing adeno-associated virus delivery to durably alter pancreatic islet cell function, with the goal of enabling long-term metabolic remission in patients with type 2 diabetes and obesity.

Fractyl Health operates as a clinical-stage biotechnology company with 101 full-time employees based in Burlington, Massachusetts. The company was incorporated in Delaware in 2010 and was formerly known as Fractyl Laboratories Inc. before rebranding in June 2021. The company is publicly listed on Nasdaq under the ticker symbol GUTS.